HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2569 Plozalizumab (Anti-CCR2 / CD192) Plozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD. Aug 10 2023
A2314 Oxelumab (Anti-TNFSF4 / OX40L / CD252) Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa. Aug 10 2023
A2571 Anti-CCL5 / RANTES Anti-CCL5 / RANTES (NI-0701) is a antibody tageting CCL5. MW:145.5 KD. Aug 10 2023
A2316 Belimumab (Anti-TNFSF13B / BAFF / CD257) Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa. Aug 10 2023
A2572 Anti-CCL20 Anti-CCL20 (GSK3050002) is a humanized IgG1κ antibody with high binding affinity to the human chemokine, CCL20. MW:145.5 KD. Aug 10 2023
A2317 Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13), with the potential to treat IgA nephropathy (IgAN). MW : 145.5 KD. Aug 10 2023
A2573 Carlumab (Anti-CCL2 / MCP1) Carlumab (Anti-CCL2 / MCP1) is a humanised monoclonal antibody targeting CCL2 with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer. MW:145.5 KD. Aug 10 2023
A2318 Anti-TNFSF12 / TWEAK Anti-TNFSF12 / TWEAK is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis. MW : 145.5 KD. Aug 10 2023
A2574 Nimacimab (Anti-CB1 / CNR1) Nimacimab (Anti-CB1/CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases. MW:145.5 KD. Aug 10 2023
A2575 Anti-CB1 / CNR1 Anti-CB1 / CNR1 (GFB-024) is a recombinant humanised monoclonal antinody that is used for targeting of CB1 receptor. MW:145.5 KD. Aug 10 2023
A2320 Pateclizumab (Anti-TNFSF1 / TNFb) Pateclizumab (Anti-TNFSF1 / TNFb) is a humanized monoclonal antibody that blocks and depletes anti-lymphotoxin α (LTα). It has a great potential for the treatment of rheumatoid arthritis (RA). MW : 145.5 KD. Aug 10 2023
A2576 Erenumab (Anti-CALCRL / CGRPR) Erenumab (Anti-CALCRL/CGRPR) is a fully human monoclonal antibody targeting CGRP receptor (calcitonin gene–related peptide receptor). Erenumab can be used for the prevention of episodic migraine. MW:145.5 KD. Aug 10 2023
A2321 Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD. Aug 10 2023
A2577 Galcanezumab (Anti-CALCA / CGRP) Galcanezumab (Anti-CALCA/CGRP) is a humanized IgG4 monoclonal antibody targeting the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research. MW:145.5 KD. Aug 10 2023
A2322 Brentuximab (Anti-TNFRSF8 / CD30) Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD. Aug 10 2023
A2578 Girentuximab (Anti-CA9 / Carbonic anhydrase 9) Girentuximab (Anti-CA9 / Carbonic anhydrase 9) is a chimeric monoclonal antibody that targets and binds to carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). MW:145.5 KD. Aug 10 2023
A2323 Varlilumab (Anti-TNFRSF7 / CD27) Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD. Aug 10 2023
A2579 Sutimlimab (Anti-C1s) Sutimlimab (Anti-C1s) is a humanized monoclonal antibody that targets the C1s protein in the classical complement pathway. It can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. MW:145.5 KD. Aug 10 2023
A2324 Iscalimab (Anti-TNFRSF5 / CD40) Iscalimab (Anti-TNFRSF5 / CD40) is a non-depleting IGg1 monoclonal antibody targeting CD40. Iscalimab can be used for research on Graves' hyperthyroidism and autoimmune diseases. MW : 145.5 KD. Aug 10 2023
A2580 Anti-C1q Anti-C1q (ANX005) is a recombinant antibody against C1q. It inhibits its function as the initiating molecule of the classical complement cascade. It is used in research of autoimmune and neurodegenerative diseases. MW:145.5 KD. Aug 10 2023